Dupixent Secures Back-to-Back COPD Approvals from US FDA and China NMPA
Regeneron (NASDAQ: REGN), a leading biopharmaceutical company based in the U.S., in collaboration with its...
Sanofi
TJ Biopharma and Sanofi Ink Deal for Anti-CD73 Antibody Uliledlimab in Greater China
TJ Biopharma, a biopharmaceutical company based in China, has entered into a licensing agreement with...
Sanofi’s Consumer Health Unit Attracts Binding Offers, Potential EUR 15 Billion Deal
French pharmaceutical giant Sanofi S.A. (EPA: SAN; NASDAQ: SNY) has reportedly received multiple binding offers...
Sanofi’s Sarclisa Secures FDA Approval for First-Line Multiple Myeloma Treatment
Sanofi (EPA: SAN; NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA)...
Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant...
Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...
Euroapi to Downsize API Production, Citing Asian Competition and Market Stagnation
Euroapi (EPA: EAPI), a French company and a spinoff from Sanofi established in 2022, has...
Sanofi’s Tolebrutinib Shows Mixed Results in Phase III Multiple Sclerosis Trials
PARIS—French pharmaceutical giant Sanofi (NASDAQ: SNY) has reported mixed outcomes from three Phase III trials...
Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of...
Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions
Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results...
Sanofi to Bolster Hyderabad Facility with $437M Investment, Eyeing Tech Upgrades
Sanofi (NASDAQ: SNY; EPA: SAN), a leading French multinational pharmaceutical company, has announced plans to...
Sanofi’s RSV Preventative Therapy Beyfortus Launches in China
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus...
Boao Lecheng Approves Use of Sanofi’s Tzield as First-Line Therapy for Type 1 Diabetes Delay
Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset...
Sanofi Invites Bids Starting at $20 Billion for Consumer Health Unit
Sanofi (NYSE: SNY) is reportedly inviting bids starting at USD 20 billion for its consumer...
Sanofi Partners with Belharra Therapeutics to Tap into Chemoproteomics for Immunology Targets
Sanofi (NASDAQ: SNY; EPA: SAN), a major French pharmaceutical company, has formed a collaboration with...
Sanofi Receives NMPA Approval for Phase III Clinical Trial of RSV Vaccine SP0125
Sanofi (EPA: SAN), a major French multinational pharmaceutical company, has announced that it has received...
Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with...
Sanofi’s Sarclisa Receives FDA Priority Review for Newly Diagnosed Multiple Myeloma Treatment
Sanofi plc (NYSE: SNY), a leading pharmaceutical company based in France, has announced that the...
Sanofi Leads Pharma Industry with AI Collaboration with Formation Bio and OpenAI
Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US...
Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion
France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ:...